» Articles » PMID: 35179046

Myocardial Cytoskeletal Adaptations in Advanced Kidney Disease

Abstract

Background The myocardial cytoskeleton functions as the fundamental framework critical for organelle function, bioenergetics and myocardial remodeling. To date, impairment of the myocardial cytoskeleton occurring in the failing heart in patients with advanced chronic kidney disease has been largely undescribed. Methods and Results We conducted a 3-arm cross-sectional cohort study of explanted human heart tissues from patients who are dependent on hemodialysis (n=19), hypertension (n=10) with preserved renal function, and healthy controls (n=21). Left ventricular tissues were subjected to pathologic examination and next-generation RNA sequencing. Mechanistic and interference RNA studies utilizing in vitro human cardiac fibroblast models were performed. Left ventricular tissues from patients undergoing hemodialysis exhibited increased myocardial wall thickness and significantly greater fibrosis compared with hypertension patients (<0.05) and control (<0.01). Transcriptomic analysis revealed that the focal adhesion pathway was significantly enriched in hearts from patients undergoing hemodialysis. Hearts from patients undergoing hemodialysis exhibited dysregulated components of the focal adhesion pathway including reduced β-actin (<0.01), β-tubulin (<0.01), vimentin (<0.05), and increased expression of vinculin (<0.05) compared with controls. Cytoskeletal adaptations in hearts from the hemodialysis group were associated with impaired mitochondrial bioenergetics, including dysregulated mitochondrial dynamics and fusion, and loss of cell survival pathways. Mechanistic studies revealed that cytoskeletal changes can be driven by uremic and metabolic abnormalities of chronic kidney disease, in vitro. Furthermore, focal adhesion kinase silencing via interference RNA suppressed major cytoskeletal proteins synergistically with mineral stressors found in chronic kidney disease in vitro. Conclusions Myocardial failure in advanced chronic kidney disease is characterized by impairment of the cytoskeleton involving disruption of the focal adhesion pathway, mitochondrial failure, and loss of cell survival pathways.

Citing Articles

Baicalein protects against heart failure by improving mitochondrial dysfunction and regulating endoplasmic reticulum stress to reduce apoptosis in vitro and in vivo.

Zhang Z, Zhang X, Yang Y, Wang H, Yang X, Xuan L Int J Immunopathol Pharmacol. 2025; 39:3946320251315800.

PMID: 39895092 PMC: 11789120. DOI: 10.1177/03946320251315800.


Elevated septal native T1 time in cardiac magnetic resonance imaging suggesting myocardial fibrosis in young kidney transplant recipients.

Ubenauf T, von der Born J, Sugianto R, Grabitz C, Lehmann E, Memaran N J Cardiovasc Magn Reson. 2025; 27(1):101839.

PMID: 39814266 PMC: 11870264. DOI: 10.1016/j.jocmr.2025.101839.


Multi-trait Analysis of GWAS for circulating FGF23 Identifies Novel Network Interactions Between HRG-HMGB1 and Cardiac Disease in CKD.

Perwad F, Akwo E, Vartanian N, Suva L, Friedman P, Robinson-Cohen C medRxiv. 2024; .

PMID: 38496593 PMC: 10942519. DOI: 10.1101/2024.03.04.24303051.


Chronic lactate exposure promotes cardiomyocyte cytoskeleton remodelling.

Luti S, Militello R, Pinto G, Illiano A, Marzocchini R, Santi A Heliyon. 2024; 10(2):e24719.

PMID: 38312589 PMC: 10835305. DOI: 10.1016/j.heliyon.2024.e24719.


Diastolic function in chronic kidney disease.

de Simone G, Mancusi C Clin Kidney J. 2023; 16(11):1925-1935.

PMID: 37915916 PMC: 10616497. DOI: 10.1093/ckj/sfad177.

References
1.
Zoccali C, Mallamaci F, Tripepi G . Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant. 2004; 19 Suppl 5:V67-72. DOI: 10.1093/ndt/gfh1059. View

2.
Liew C, Dzau V . Molecular genetics and genomics of heart failure. Nat Rev Genet. 2004; 5(11):811-25. DOI: 10.1038/nrg1470. View

3.
Fan D, Takawale A, Lee J, Kassiri Z . Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012; 5(1):15. PMC: 3464725. DOI: 10.1186/1755-1536-5-15. View

4.
Leifheit-Nestler M, Richter B, Basaran M, Nespor J, Vogt I, Alesutan I . Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23. Front Endocrinol (Lausanne). 2018; 9:333. PMC: 6021503. DOI: 10.3389/fendo.2018.00333. View

5.
London G, Fabiani F, Marchais S, De Vernejoul M, Guerin A, Safar M . Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int. 1987; 31(4):973-80. DOI: 10.1038/ki.1987.94. View